Skip to main content
Log in

BDG surveillance and preemptive antifungals cost effective in ICUs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2015 US dollars

Reference

  • Pang YK, et al. Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis. European Journal of Clinical Microbiology and Infectious Diseases : 29 Sep 2016. Available from: URL: http://doi.org/10.1007/s10096-016-2796-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

BDG surveillance and preemptive antifungals cost effective in ICUs. PharmacoEcon Outcomes News 764, 8 (2016). https://doi.org/10.1007/s40274-016-3457-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3457-7

Navigation